Zelira Therapeutics Ltd is a clinical-stage biotechnology company focused on the development and commercialization of proprietary cannabinoid-based therapies. The company leverages a portfolio of clinical and preclinical drug candidates designed to address unmet medical needs in areas such as chronic pain, autism spectrum disorder, Alzheimer’s disease and sleep disorders. Utilizing patented formulation and delivery platforms, Zelira aims to optimize efficacy and safety profiles of plant-derived cannabinoids.
The company pursues a dual geography strategy through its Australian and North American operations. In Australia, Zelira Therapeutics collaborates with academic and research institutions to advance clinical trials and regulatory approvals. In North America, the company engages with strategic partners, healthcare providers and regulatory bodies to progress its lead programs toward commercialization. Key products in development include gel formulations, oral capsules and transdermal patches tailored for pediatric and adult patient populations.
Zelira’s product pipeline encompasses both prescription-focused drug candidates and wellness offerings. Its clinical portfolio includes novel cannabinoid combinations targeting neurodevelopmental conditions, while early-stage research explores formulations for mood and cognitive disorders. The company’s R&D efforts are underpinned by expertise in pharmacology, formulation science and regulatory strategy, with a focus on achieving scalable manufacturing and global market access.
Headquartered in Melbourne, Australia, Zelira Therapeutics was founded to bridge the gap between botanical science and pharmaceutical-grade products. The executive team combines experience in biotech innovation, clinical development and commercial operations. Through ongoing trials, strategic collaborations and regulatory engagements, Zelira aims to establish itself as a leader in cannabinoid therapeutics for both medical and wellness markets.
AI Generated. May Contain Errors.
